Vorinostat-induced bone loss might be related to drug toxicity

Bone. 2013 Dec;57(2):384-5. doi: 10.1016/j.bone.2013.08.024. Epub 2013 Aug 30.

Authors

Song Xu¹, Kim De Veirman, Karin Vanderkerken, Ivan Van Riet

Affiliation

¹ Department of Lung Cancer Surgery, Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, PR China; Stem Cell Laboratory-Division Clinical Hematology, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium; Department of Hematology and Immunology, Vrije Universiteit Brussel (VUB), Myeloma Center Brussels, Brussels, Belgium.

PMID: 23999199
DOI: 10.1016/j.bone.2013.08.024

No abstract available

Publication types

Letter

MeSH terms

Animals
Bone Resorption / chemically induced*
Drug Administration Schedule
Gene Expression Regulation / drug effects
Histone Deacetylase Inhibitors / adverse effects
Humans
Hydroxamic Acids / administration & dosage
Hydroxamic Acids / adverse effects*
Inhibitory Concentration 50
Mesenchymal Stem Cells / cytology
Mice
Osteogenesis / drug effects
Osteogenesis / genetics
Vorinostat

Substances

Histone Deacetylase Inhibitors
Hydroxamic Acids
Vorinostat